{"id":"treosulfan","rwe":[],"_fda":{"id":"2d06b03c-17aa-0492-e063-6294a90abd8f","set_id":"2d06b03c-17aa-0492-e063-6294a90abd8f","openfda":{"unii":["CO61ER3EPI"],"route":["INTRAVENOUS"],"rxcui":["2703570","2703575","2703577","2703579"],"spl_id":["2d06b03c-17aa-0492-e063-6294a90abd8f"],"brand_name":["GRAFAPEX"],"spl_set_id":["2d06b03c-17aa-0492-e063-6294a90abd8f"],"package_ndc":["59137-335-01","59137-365-01"],"product_ndc":["59137-335","59137-365"],"generic_name":["TREOSULFAN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TREOSULFAN"],"manufacturer_name":["Medexus Pharma, Inc."],"application_number":["NDA214759"],"is_original_packager":[true]},"version":"1","overdosage":["10 OVERDOSAGE The principal toxic effect of treosulfan in cases of overdose are myeloablation and prolonged pancytopenia, mucositis, skin toxicity, nausea, vomiting and gastritis. In case of overdosage, monitor blood counts frequently and provide vigorous supportive measures as medically indicated."],"references":["15 REFERENCES “OSHA Hazardous Drugs.” OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html"],"description":["11 DESCRIPTION GRAFAPEX for injection contains treosulfan, an alkylating drug. Treosulfan is known chemically as L-‑threitol ‑1,4-‑dimethanesulfonate. Treosulfan is soluble in water (7% m/v) at 25ᴼC. Treosulfan is not hygroscopic.Treosulfan has the molecular formula C 6 H 14 O 8 S 2 and a molecular weight of 278.3 g/mole. Treosulfan has the following chemical structure: GRAFAPEX is intended for intravenous administration. It is supplied as a white, sterile, lyophilized powder for injection in glass vials containing 1 g or 5 g treosulfan. Treosulfan Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied GRAFAPEX (treosulfan) for injection is a white, sterile, lyophilized powder for reconstitution. It is supplied in a carton containing one single-dose vial. Presentation NDC 1 g/vial 59137-335-01 5 g/vial 59137-365-01 Storage and Handling Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. (Excursions permitted between 15°C and 30°C) GRAFAPEX is a hazardous drug. Follow applicable special handling and disposal procedures 1 ."],"boxed_warning":["WARNING: MYELOSUPPRESSION GRAFAPEX causes severe and prolonged myelosuppression at the recommended dosage. Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters [see Warnings and Precautions ( 5.1 )] . WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. GRAFAPEX causes severe and prolonged myelosuppression. Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters. ( 5.1 )"],"effective_time":"20250131","clinical_studies":["14 CLINICAL STUDIES The efficacy of GRAFAPEX was evaluated in a randomized active-controlled trial (MC‑FludT.14/L Trial II; NCT00822393 ) comparing GRAFAPEX to busulfan in combination with fludarabine as a preparative regimen for allogeneic transplantation. Eligible patients included adults 18 to 70 years old with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Karnofsky performance status > 60%, and age ≥ 50 years or hematopoietic cell transplantation comorbidity index [HCT‑CI] score > 2. Patients were excluded if the creatinine clearance was < 60 mL/min, forced expiratory volume (FEV1) < 50% or on supplemental oxygen, left ventricular ejection fraction (LVEF) < 40%, bilirubin > 3X ULN, or aminotransferases (ALT or AST) > 5X ULN. The patients were randomized to receive GRAFAPEX 10 g/m² daily on day -4, -3 and -2 or to busulfan 0.8 mg/kg every 6 hours on day -4 and -3 in combination with fludarabine 30 mg/m 2 daily on day -6, -5, -4, -3 and -2, and hematopoietic stem cell transplantation on day 0. For the subset of patients with unrelated donors, antithymocyte globulin was administered in 97% and 95% of patients on each arm, respectively. Cyclosporine and methotrexate was used as graft‑vs‑host disease prophylaxis. There were 570 patients randomized to GRAFAPEX (n = 280) or busulfan (n = 290). The efficacy population included 365 patients with AML and 205 patients with MDS: 536 patients received peripheral blood stem cells, 15 patients received marrow stem cells, and 19 patients were not transplanted. Table 5 shows the baseline characteristics of the study patients. Table 5: Baseline characteristics of the study patients (MC‑FludT.14/L Trial II) Baseline Characteristics GRAFAPEX (n = 280) Busulfan (n = 290) Age, median (range), years 60.0 (37, 70) 60.5 (31, 70) Age, n (%) 18-64 years 65-70 years 204 (73%) 76 (27%) 218 (75%) 72 (25%) Gender, n (%) Male Female 171 (61%) 109 (39%) 176 (61%) 114 (39%) Weight, median (range), kg 80.0 (48.0, 144.0) 78.1 (46.0, 141.9) Disease, n (%) AML MDS 192 (69%) 88 (31%) 173 (60%) 117 (40%) AML remission status, n (%) CR1 >CR1 164 (85%) 28 (15%) 148 (86%) 25 (14%) MDS risk group, n (%) Lower risk Higher risk 20 (23%) 68 (77%) 20 (17%) 97 (83%) HCT‑CI score ≤2 >2 116 (41%) 164 (59%) 118 (41%) 172 (59%) Donor Matched related Matched unrelated 66 (24%) 214 (76%) 68 (23%) 222 (77%) Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; CR1: complete remission 1; HCT-CI: hematopoietic cell transplant-specific comorbidity index Efficacy was established on the basis of overall survival (OS), defined as the time from randomization until death from any cause. The hazard ratio (HR) for OS (stratified by donor type and risk group) compared to busulfan was 0.67 (95% CI: 0.51, 0.90) in the randomized population, 0.73 (95% CI: 0.51, 1.06) in patients with AML, and 0.64 (95% CI: 0.40, 1.02) in patients with MDS. Results are displayed in Figures 1, 2, and 3 below. Figure 1: Kaplan-Meier estimates of overall survival since time of randomization MC FludT.14/L Trial II Figure 2: Kaplan-Meier estimates of overall survival since time of randomization MC FludT.14/L Trial II (patients with AML) Figure 3: Kaplan-Meier estimates of overall survival since time of randomization MC FludT.14/L Trial II (patients with MDS) Figure 1 Figure 2 Figure 3"],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions ( 5.1 )] Seizures [see Warnings and Precautions ( 5.2 )] Skin Disorders [see Warnings and Precautions ( 5.3 )] Injection Site Reactions and Tissue Necrosis [see Warnings and Precautions ( 5.4 )] Secondary Malignancies [see Warnings and Precautions ( 5.5 )] The most common adverse reactions (≥20%) are musculoskeletal pain, stomatitis, pyrexia, nausea, edema, infection, and vomiting. ( 6.1 ) Selected Grade 3 or 4 nonhematological laboratory abnormalities are increased GGT, increased bilirubin, increased ALT, increased AST, and increased creatinine. To report SUSPECTED ADVERSE REACTIONS, contact Medexus Pharma, Inc. at 1-855-336 -3322 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. MC‑FludT.14/L Trial II The safety of GRAFAPEX was evaluated in 553 adult patients with AML and MDS in a randomized trial (MC‑FludT.14/L Trial II) comparing GRAFAPEX in combination with fludarabine to busulfan in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation. The patients were randomized to receive GRAFAPEX (n=270) 10 g/m² daily on day -4, -3 and -2 or to busulfan (n=283) 0.8 mg/kg every 6 hours on day -4 and -3 in combination with fludarabine 30 mg/m 2 daily on day -6, -5, -4, -3 and -2, and hematopoietic stem cell transplantation on day 0 [see Clinical Studies ( 14 )] . Fatal regimen-related adverse reactions occurred within 30 days of transplantation in 1.9% of patients on the GRAFAPEX arm. All fatalities were due to pulmonary adverse reactions. The most common adverse reactions (≥20%) in patients treated with GRAFAPEX were musculoskeletal pain, stomatitis, pyrexia, nausea, edema, infection, and vomiting. Selected Grade 3 or 4 nonhematological laboratory abnormalities were increased GGT, increased bilirubin, increased ALT, increased AST, and increased creatinine. Table 3 shows the adverse reactions in Study MC‑FludT.14/L Trial II through transplant Day +30. Table 3: Adverse Reactions in ≥10% of Patients through Transplant Day +30 in Study MC-FludT.14/L Trial II Adverse Reaction* All Grades Grades 3 or 4 GRAFAPEX (N = 270) Busulfan (N = 283) GRAFAPEX (N = 270) Busulfan (N = 283) % % % % Musculoskeletal pain 39 27 5 2 Stomatitis 38 48 6 7 Pyrexia 34 36 1 3 Nausea 33 41 3 6 Edema 29 18 0.7 1 Infection 1 23 18 12 6 Vomiting 22 19 1 1 Rash 17 13 1 1 Diarrhea 17 18 1 1 Headache 16 18 1 1 Febrile neutropenia 15 11 15 11 Abdominal pain 15 13 3 2 Hypertension 14 21 8 10 Hemorrhage 14 14 1 1 Fatigue 13 15 1 0.4 Constipation 12 12 0.4 0 Tachycardia 10 5 1 2 Hepatotoxicity 10 8 4 3 *Includes grouped terms 1 Includes fatalities: n=6 in the GRAFAPEX arm and n=2 in the busulfan arm Grading is based on Common Terminology Criteria for Adverse Events version 4.03 Clinically relevant adverse reactions in <10% of patients who received GRAFAPEX included: Neoplasms benign, malignant and unspecified (including cysts and polyps): second malignancy Metabolism and nutrition disorders: Decreased appetite, impaired glucose tolerance Psychiatric disorders: Insomnia, confusional state, agitation Nervous system disorders: Paresthesia, dizziness Ear and labyrinth disorders: Vertigo Cardiac disorders: Cardiac failure, pericardial effusion Vascular disorders: Flushing, embolism, hypotension Respiratory, thoracic and mediastinal disorders: Pneumonitis, pleural effusion, pharyngeal or laryngeal inflammation, dyspnea, cough, oropharyngeal pain, hiccups, dysphonia Gastrointestinal disorders: Oral pain, gastritis, dyspepsia, dysphagia, abdominal distension, dry mouth Skin and subcutaneous tissue disorders: Palmar plantar erythrodysesthesia syndrome, pruritus, erythema, dermatitis, skin hyperpigmentation, dry skin Renal and urinary disorders: Acute kidney injury, hematuria, urinary tract pain General disorders and administration site conditions: Chills, pain Investigations: Weight decreased or increased, increase of C‑reactive protein All patients treated with GRAFAPEX and fludarabine developed neutropenia, anemia, and thrombocytopenia. One patient on the GRAFAPEX arm had graft failure. Table 4 summarizes the selected nonhematological laboratory abnormalities in Study MC-FludT.14/L Trial II by treatment arm through Day +30 posttransplant. Table 4. Selected Grades 3-4 Laboratory Abnormalities through Transplant Day +30 in Study MC-FludT.14/L Trial II Laboratory Abnormality GRAFAPEX N = 270 % Busulfan N = 283 % Gamma Glutamyl Transferase Increased 16 28 Bilirubin Increased 6 5 Alanine Aminotransferase Increased 6 4 Aspartate Aminotransferase Increased 4 1 Creatinine Increased 3 0.7 Grading is based on Common Terminology Criteria for Adverse Events version 4.03 6.2 Postmarketing Experience The following additional adverse reactions have been identified during post approval use of GRAFAPEX in preparative regimens prior to hematopoietic stem cell transplantation in adult and pediatric patients in other countries. As these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Metabolism and Nutrition Disorders: Acidosis Nervous system disorders: Peripheral sensory neuropathy Renal and urinary disorders: Renal failure Immune system disorders: Hypersensitivity"],"contraindications":["4 CONTRAINDICATIONS GRAFAPEX is contraindicated in patients with hypersensitivity to any component of the drug product. Hypersensitivity to any component of the drug product. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Certain CYP2C19 and CYP3A4 Substrates: Monitor for adverse reactions of these substrates where minimal concentration changes may lead to serious or life-threatening toxicities. ( 7.1 ) 7.1 Effect of GRAFAPEX on Other Drugs Certain CYP2C19 and CYP3A4 Substrates Monitor for adverse reactions of certain CYP2C19 or CYP3A4 substrates where minimal concentration changes may lead to serious or life-threatening toxicities, and reduce the dosage, as needed, if recommended in the prescribing information of these substrates. Treosulfan is a CYP2C19 and CYP3A4 inhibitor [see Clinical Pharmacology ( 12 )] . Concomitant use of GRAFAPEX is predicted to increase the exposure of CYP2C19 and CYP3A4 substrates based on a mechanistic understanding of treosulfan metabolism, which may increase the risk of their adverse reactions."],"how_supplied_table":["
PresentationNDC
1 g/vial59137-335-01
5 g/vial59137-365-01
"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Treosulfan is an alkylating agent. DNA alkylation is thought to be responsible for the cytotoxic activities of treosulfan. Treosulfan showed hematopoietic stem cell depleting activity as well as immunosuppressive and antitumor activity in mouse models of leukemia. 12.2 Pharmacodynamics Increase in treosulfan exposure was associated with an increased incidence of infection-related death. Treosulfan time course of pharmacodynamic response is unknown. 12.3 Pharmacokinetics Treosulfan pharmacokinetic parameters were observed at the approved recommended dosage, unless otherwise specified. Treosulfan is a prodrug. Treosulfan mean ± SD area under the curve (AUC) is 1,200 ± 211 hr mcg/mL. There was no dose accumulation. Distribution Treosulfan mean (CV%) volume of distribution is approximately 41 liters (CV%: 19%). Treosulfan does not bind to plasma albumin. Elimination Treosulfan mean (± standard deviation) terminal half-life is 1.7 ± 0.4 hours. Metabolism The pharmacologically inactive treosulfan is converted spontaneously under physiological conditions into the active monoepoxide intermediate (2S,3S)‑1,2‑epoxybutane‑3,4‑diol‑4‑methanesulfonate) and finally to active L‑diepoxibutane (2S,3S)‑1,2:3,4‑diepoxybutane). Excretion A median of 42% of the treosulfan dose is excreted unchanged in the urine within 24 hours, and 89% of this unchanged fraction is excreted within the first 8 hours after administration. Specific Populations No clinically significant differences in the pharmacokinetics of treosulfan based on sex, mild renal impairment (CLcr 60‑89 mL/min), or mild hepatic impairment (total bilirubin less than or equal to ULN with AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST). The effect of moderate or severe renal impairment, moderate or severe hepatic impairment, and age ≥ 65 years on treosulfan pharmacokinetics is unknown. Pediatric Patients Treosulfan exposure in pediatric patients with BSA < 0.7 m 2 and with BSA 0.7 to < 1.1 m 2 are 11% and 5% higher, respectively, compared to adults. No clinically significant difference in treosulfan median terminal half‑life was observed between pediatric patients and adults. The median terminal half‑life of the active monoepoxide intermediate was 1.6 hrs in pediatric patients. Drug Interaction Studies In Vitro Studies CYP Enzymes : Treosulfan is a CYP2D6 substrate and its monoepoxide intermediate is a CYP2C8 substrate. Treosulfan inhibits CYP2C19 and CYP3A4 (using midazolam as substrate), but does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, or CYP3A4 (using testosterone as substrate). Transporter Systems : Treosulfan does not inhibit BCRP, BSEP, MATE1, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, or OCT2."],"indications_and_usage":["1 INDICATIONS AND USAGE GRAFAPEX is an alkylating drug indicated for: Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML). ( 1.1 ). Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS). ( 1.2 ). 1.1 Acute Myeloid Leukemia GRAFAPEX is indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML). 1.2 Myelodysplastic Syndrome GRAFAPEX is indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS)."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Seizures: Monitor signs of neurological adverse reactions and consider clonazepam prophylaxis for patients at higher risk. ( 5.2 ) Skin disorders: Keep skin clean and dry on days of GRAFAPEX infusion and change occlusive dressings after infusion. Change diapers frequently during the 12 hours after each infusion of GRAFAPEX. ( 5.3 ) Injection Site Reactions and Tissue Necrosis: May cause local tissue necrosis and injection site reactions, including erythema, pain, and swelling, in case of extravasation. If extravasation occurs, stop the infusion immediately and manage medically as required. ( 5.4 ) Secondary Malignancies: There is an increased risk of a secondary malignancy with use of GRAFAPEX. ( 5.5 ) Increased Early Morbidity and Mortality at Dosages Higher than Recommended: Avoid exceeding the recommended dosage of 10 g/m 2 daily for three consecutive days. ( 5.6 ) Embryo-fetal toxicity: Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.7 , 8.1 , 8.3 ) 5.1 Myelosuppression Profound myelosuppression with pancytopenia is the desired therapeutic effect of GRAFAPEX-based preparative regimens, occurring in all patients. Time to neutrophil counts > 0.5 Gi/L occurred at a median of 18 days (range 7-42 days) after allogeneic hematopoietic stem cell transplantation in adult patients treated using GRAFAPEX in combination with fludarabine as the preparative regimen. Do not begin the preparative regimen if the stem cell donor is not available. Monitor blood cell counts daily until hematopoetic recovery. Provide standard supportive care for infections, anemia and thrombocytopenia until there is adequate hematopoietic recovery. 5.2 Seizures There have been reports of seizures in patients following treatment with treosulfan. Monitor patients for signs of neurological adverse reactions. Clonazepam prophylaxis may be considered for patients at higher risk for seizures, including infants. 5.3 Skin Disorders An increase of skin disorders (e.g. rash, dermatitis) was observed when patients received sodium bicarbonate-containing hydration in the course of treosulfan infusion, potentially because of acceleration of the pH‑dependent formation of alkylating epoxides [see Adverse Reactions ( 6.1 ) and Clinical Pharmacology ( 12.1 )]. Keep skin clean and dry on days of GRAFAPEX infusion. Diaper dermatitis may occur because of excretion of treosulfan in the urine. Change diapers frequently during the 12 hours after each infusion of GRAFAPEX. Dermatitis may occur under occlusive dressings; change occlusive dressings after each infusion of GRAFAPEX. 5.4 Injection Site Reactions and Tissue Necrosis GRAFAPEX may cause local tissue necrosis and injection site reactions, including erythema, pain, and swelling, in case of extravasation. Assure venous access patency prior to starting GRAFAPEX infusion, and monitor the intravenous infusion site for redness, swelling, pain, infection, and necrosis during and after administration of GRAFAPEX. If extravasation occurs, stop the infusion immediately and manage medically as required. Do not administer by the intramuscular or subcutaneous routes. 5.5 Secondary Malignancies There is an increased risk of a secondary malignancy with use of GRAFAPEX. Treosulfan is carcinogenic and genotoxic [see Nonclinical Toxicology ( 13.1 )] . The risk of secondary malignancy is increased in patients with Fanconi anemia and other DNA breakage disorders. The safety and efficacy of GRAFAPEX have not been established for patients with these disorders. 5.6 Increased Early Morbidity and Mortality at Dosages Higher than Recommended In MC‑FludT.14/L Trial I (NCT00822393), 330 adult patients were randomized to treosulfan at 14 g/m 2 /day (1.4 times the recommended dose) for three consecutive days or busulfan at 3.2 mg/kg/day for two days, in combination with fludarabine as a preparative regimen for allogeneic transplantation. This trial was discontinued early due to a higher incidence of early fatal and/or serious adverse reactions in patients receiving treosulfan. Avoid exceeding the recommended GRAFAPEX dosage of 10 g/m 2 daily for three consecutive days. 5.7 Embryo-Fetal Toxicity Based on its mechanism of action, GRAFAPEX can cause fetal harm when administered to a pregnant woman because it is genotoxic and affects dividing cells [see Clinical Pharmacology ( 12 ) and Nonclinical Toxicology ( 13 )]. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 6 months following the last dose of GRAFAPEX. Advise males with female partners of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 3 months after the last dose [see Use in Specific Populations ( 8.1 ) and ( 8.3 )]."],"clinical_studies_table":["
Table 5: Baseline characteristics of the study patients (MC‑FludT.14/L Trial II)
Baseline CharacteristicsGRAFAPEX (n = 280)Busulfan (n = 290)
Age, median (range), years60.0 (37, 70)60.5 (31, 70)
Age, n (%)18-64 years65-70 years 204 (73%) 76 (27%)218 (75%)72 (25%)
Gender, n (%)MaleFemale171 (61%) 109 (39%) 176 (61%) 114 (39%)
Weight, median (range), kg80.0 (48.0, 144.0)78.1 (46.0, 141.9)
Disease, n (%) AML MDS192 (69%)88 (31%)173 (60%)117 (40%)
AML remission status, n (%)CR1>CR1164 (85%)28 (15%) 148 (86%)25 (14%)
MDS risk group, n (%) Lower riskHigher risk20 (23%)68 (77%) 20 (17%)97 (83%)
HCT‑CI score≤2>2116 (41%)164 (59%) 118 (41%)172 (59%)
DonorMatched relatedMatched unrelated66 (24%)214 (76%) 68 (23%)222 (77%)
Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; CR1: complete remission 1; HCT-CI: hematopoietic cell transplant-specific comorbidity index
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis and Mutagenesis No carcinogenicity study has been conducted. Treosulfan was mutagenic in the in vitro bacterial mutagenicity assay (Ames test) and clastogenic in the in vitro micronucleus assay in human lymphocytes. No dedicated animal fertility studies were conducted. In a general toxicity study in rats, animals were treated with 5 or 50 mg/kg/day treosulfan orally for 7 months, 6 days a week. Spermatogenesis and ovarian function were significantly affected, starting at 5 mg/kg (0.003‑fold the human dose based on BSA). Findings included reduced weight of the testicles, seminal vesicle, prostate, and uterus, as well as spermatogenesis reduction and arrest, uterine atrophy, and reduced or absent corpora lutea and follicles."],"adverse_reactions_table":["
Table 3: Adverse Reactions in ≥10% of Patients through Transplant Day +30 in Study MC-FludT.14/L Trial II
Adverse Reaction*All GradesGrades 3 or 4
GRAFAPEX(N = 270)Busulfan(N = 283)GRAFAPEX(N = 270)Busulfan(N = 283)
% % % %
Musculoskeletal pain 39 27 5 2
Stomatitis 38 48 6 7
Pyrexia 34 36 1 3
Nausea 33 41 3 6
Edema 29 18 0.7 1
Infection 1 23 18 12 6
Vomiting 22 19 1 1
Rash 17 13 1 1
Diarrhea 17 18 1 1
Headache 16 18 1 1
Febrile neutropenia 15 11 15 11
Abdominal pain 15 13 3 2
Hypertension 14 21 8 10
Hemorrhage 14 14 1 1
Fatigue 13 15 1 0.4
Constipation 12 12 0.4 0
Tachycardia 10 5 1 2
Hepatotoxicity 10 8 4 3
*Includes grouped terms 1Includes fatalities: n=6 in the GRAFAPEX arm and n=2 in the busulfan arm Grading is based on Common Terminology Criteria for Adverse Events version 4.03
","
Table 4. Selected Grades 3-4 Laboratory Abnormalities through Transplant Day +30 in Study MC-FludT.14/L Trial II
Laboratory AbnormalityGRAFAPEX N = 270 %Busulfan N = 283 %
Gamma Glutamyl Transferase Increased1628
Bilirubin Increased65
Alanine Aminotransferase Increased64
Aspartate Aminotransferase Increased41
Creatinine Increased30.7
Grading is based on Common Terminology Criteria for Adverse Events version 4.03
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Infections Inform patients of the increased risk of infections after treatment with GRAFAPEX that may require antibiotic, antiviral, or antifungal treatment and hospitalization. Advise patients to contact their healthcare provider immediately in case of any new or worsening signs of infection, e.g., cough, headache, diarrhea, or fever [see Warnings and Precautions ( 5.1 )] . Seizures Inform patients that seizures may occur [ see Warnings and Precautions ( 5.2 )] . Skin Disorders Advise patients to clean “sweaty” skin parts (armpit, groin, genital area, inframammary line), each with a disposable washcloth and clear water. Advise patients not to apply any cream to the skin on the days of chemotherapy, and clothing should not be too tight, in order to let the skin “breathe” [see Warnings and Precautions ( 5.3 )] . Secondary Malignancies Inform patients of the possible risk of a second malignancy [see Warnings and Precautions ( 5.5 )] . Embryo-Fetal Toxicity Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 6 months following the last dose of GRAFAPEX [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.3 )] . Advise males with female partners of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 3 months after the last dose [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.3 )] . Lactation Advise women not to breastfeed during treatment with GRAFAPEX and for 1 week after the last dose [see Use in Specific Populations ( 8.2 )]. Infertility GRAFAPEX can impair fertility in females and males, and may cause temporary or permanent infertility [see Use in Specific Populations ( 8.3 )] . Manufactured for: Medexus Pharma, Inc. Chicago, Illinois 60606 USA GRAFAPEX™ is a trademark of medac GmbH, Germany."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended dosage: 10 g/m² body surface area (BSA) per day as a two hour intravenous infusion, given on three consecutive days (day -4, -3, -2) in conjunction with fludarabine before hematopoietic stem cell infusion (day 0). ( 2.1 , 2.2 ) See Full Prescribing Information for instructions on preparation and administration. ( 2.2 ) 2.1 Recommended Dosage The recommended dosage of GRAFAPEX is 10 g/m 2 by intravenous infusion given daily for three days, beginning on Day -4 prior to transplantation in combination with fludarabine as outlined in Table 1. Table 1: Dosage Regimen for GRAFAPEX-Based Allogeneic HSCT Treatment Day -6 Day -5 Day -4 Day-3 Day -2 Day -1 Day 0 GRAFAPEX 10 g/m 2 /day intravenous infusion X X X Fludarabine 30 mg/m 2 /day intravenous infusion X X X X X Allogeneic hematopoietic stem cell infusion X Premedicate patients with antiemetics prior to the first dose of GRAFAPEX and continue antiemetics on a fixed schedule through completion of treosulfan administration. 2.2 Preparation and Administration Instructions Reconstitute GRAFAPEX prior to intravenous infusion. GRAFAPEX is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Use aseptic technique to prepare GRAFAPEX. Calculate the dose, the total volume of reconstituted GRAFAPEX solution required, and the number of GRAFAPEX vials needed. Reconstitute each vial with 0.45% Sodium Chloride Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or Sterile Water for Injection, in its original glass container using volumes described in Table 2 to obtain a final concentration of approximately 0.05 g/mL of GRAFAPEX. Reconstitution with Sterile Water for Injection alone is not recommended in children less than or equal to 12 years of age due to the resulting hypo-osmolarity of the final solution. Table 2: Reconstitution Solution Volume Strength Volume 1 g/vial 20 mL 5 g/vial 100 mL Shake the vial(s) to dissolve. Inspect the reconstituted solution for discoloration and particulate matter. The reconstituted solution appears as a clear colorless solution. Solutions showing any sign of precipitation should not be used. In case that solubility issues occur, prolonged standing time or slight warming of the reconstituted solution (hand warm) may be useful. Determine the volume of 0.05 g/mL reconstituted solution needed based on the required dose. Reconstituted solutions of GRAFAPEX may be combined into a larger glass vial, ethylene-vinyl acetate (EVA) bag or polyolefin (PO) bag. Discard any unused portion left in the vial(s). If not used immediately store reconstituted GRAFAPEX solution at room temperature 20°C to 25°C (68°F to 77°F) for up to 24 hours. Do not use if the solution contains a precipitate. Do not refrigerate. Infuse GRAFAPEX intravenously over 2 hours. Confirm patency of the intravenous line prior to infusion. Monitor for extravasation; if extravasation occurs, stop the infusion [see Warnings and Precautions ( 5.4 )] ."],"spl_product_data_elements":["GRAFAPEX treosulfan TREOSULFAN TREOSULFAN GRAFAPEX treosulfan TREOSULFAN TREOSULFAN"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS For injection: 1 g/vial or 5 g/vial treosulfan as a white, sterile, lyophilized powder in single-dose vials for reconstitution. For injection: 1 g/vial and 5 g/vial treosulfan as a lyophilized powder in a single-dose vial. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on its mechanism of action, GRAFAPEX can cause fetal harm when administered to a pregnant woman because it is genotoxic and affects dividing cells [see Clinical Pharmacology ( 12 ) and Nonclinical Toxicology ( 13 )] . There are no available human clinical data on the use of treosulfan in pregnant women to support an estimation of a drug-associated risk. Specific embryo-fetal developmental toxicity studies with treosulfan in animals were not conducted. Advise pregnant women of the potential risk to a fetus [see Data]. In the U.S. general population, the estimated background risk of major birth defects is 2% – 4% and of miscarriage is 15% – 20% of clinically recognized pregnancies. Data Animal Data Animal reproductive or developmental toxicity studies were not conducted with treosulfan. Treosulfan is genotoxic and is toxic to dividing cells, suggesting it can cause embryotoxicity and teratogenicity. 8.2 Lactation Risk Summary There is no data on the presence of treosulfan or its metabolites in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with GRAFAPEX and for 1 week after the last dose. 8.3 Females and Males of Reproductive Potential Based on its mechanism of action, GRAFAPEX can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )]. Pregnancy Testing Conduct pregnancy testing in females of reproductive potential within 7 days prior to initiating therapy with GRAFAPEX. Contraception Females Advise females of reproductive potential to use effective contraception during and up to 6 months after treatment with GRAFAPEX. Males Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with GRAFAPEX and for 3 months after the last dose [see Nonclinical Toxicology ( 13.1 )] Infertility Based on findings in animal studies, GRAFAPEX can impair fertility in females and males, and may cause temporary or permanent infertility [see Nonclinical Toxicology ( 13.1 )] . 8.4 Pediatric Use The safety and efficacy of GRAFAPEX as part of a preparative regimen prior to allogeneic hematopoietic stem cell transplant in pediatric patients 1 year of age and older with AML or MDS have been established based on evidence from an adequate and well-controlled study in adults, with additional pharmacokinetic and safety data in 111 pediatric patients, including 22 infants (1 month to < 2 years), 54 children (2 to < 12 years), and 35 adolescents (12 to < 17 years) [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ), and Clinical Studies ( 14 )] . The incidence of hepatic and gastrointestinal adverse reactions was higher in pediatric patients than in adults. Safety and effectiveness of GRAFAPEX as part of a preparative regimen prior to allogeneic hematopoietic stem cell transplant in pediatric patients with AML or MDS younger than 1 year of age have not been established. Juvenile Animal Toxicity Data Treatment of juvenile rats from postnatal day (PND) 10 to 35 with daily doses of 10, 50 or 100 mg/kg treosulfan (approximately 0.006, 0.03, 0.06-‑fold the human dose based on body surface area, BSA) generally resulted in findings comparable to those seen in adult animals. A delayed physical development indicated by decreased body weight, reduced relative organs weights, and delayed time point of vaginal opening were noted in the high-dosed rats. In a separate study, single intravenous administrations of 500 mg/kg treosulfan (0.3-‑fold the human dose based on BSA) to juvenile (PND 10) and young adult (PND 34 – 35) rats, treosulfan concentrations in brain tissue were low compared to plasma concentrations, but were approximately 2- to 3-fold higher in juvenile rats (4-6%) in comparison to young adults (2-3%). 8.5 Geriatric Use Of the total number of GRAFAPEX-treated patients with AML or MDS in Study MC-FludT.14/L Trial II (n=270), 73 (27%) were 65 to 74 years of age, and none were 75 years of age and older [see Clinical Studies ( 14 )] . No significant differences in safety or effectiveness were observed between these subjects and younger subjects."],"dosage_and_administration_table":["
Table 1: Dosage Regimen for GRAFAPEX-Based Allogeneic HSCT
TreatmentDay -6Day -5Day -4 Day-3Day -2Day -1Day 0
GRAFAPEX 10 g/m 2/day intravenous infusion XXX
Fludarabine 30 mg/m 2/day intravenous infusion XXXXX
Allogeneic hematopoietic stem cell infusionX
","
Table 2: Reconstitution Solution Volume
StrengthVolume
1 g/vial20 mL
5 g/vial100 mL
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - GRAFAPEX™ 1 g Carton Label - GRAFAPEX™ 1 g NDC 59137- 335 -01 GRAFAPEX™ (treosulfan) for injection 1 g/vial For intravenous infusion after reconstitution WARNING: Hazardous Drug One Single-dose Vial. Discard Unused Portion. Rx only One Single-dose Vial Vial Label - GRAFAPEX™ 1 g NDC 59137 -335- 00 GRAFAPEX™ (treosulfan) for injection 1 g/vial For intravenous infusion after reconstitution WARNING: Hazardous Drug Single-dose Vial. Discard Unused Portion. Recommended dosage: See Prescribing Information. Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Do not use if solution contains a precipitate. Rx only Manufactured for: Medexus Pharma, Inc. Chicago, IL 60606 USA Manufactured by: Oncotec Pharma Produktion GmbH, Dessau-Roβlau, Germany Grafapex 1g Carton Grafapex 1g Vial","PRINCIPAL DISPLAY PANEL - GRAFAPEX™ 5 g Carton Label - GRAFAPEX™ 5 g NDC 59137- 365 -01 GRAFAPEX™ (treosulfan) for injection 5 g/vial For intravenous infusion after reconstitiution WARNING: Hazardous Drug One Single-dose Vial. Discard Unused Portion. Rx only Vial Label - GRAFAPEX™ 5 g NDC 59137- 365 -00 GRAFAPEX™ (treosulfan) for injection 5 g/vial For intravenous infusion after reconstitution WARNING: Hazardous Drug Single-dose Vial. Discard Unused Portion. Recommended dosage: See Prescribing Information. Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Do not use if solution contains a precipitate. Rx only Manufactured for: Medexus Pharma, Inc. Chicago, IL 60606 USA Manufactured by: Oncotec Pharma Produktion GmbH, Dessau-Roβlau, Germany Grafapex 5g Carton Grafapex 5g Vial"]},"tags":[{"label":"treosulfan","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01AB02","category":"atc"},{"label":"LOE Approaching","category":"status"},{"label":"Allogeneic peripheral blood stem cell transplant","category":"indication"},{"label":"Medexus","category":"company"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: MYELOSUPPRESSION GRAFAPEX causes severe and prolonged myelosuppression at the recommended dosage. Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters [see Warnings and Precautions ( 5.1 )] . WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. GRAFAPEX causes severe and prolonged myelosuppression. Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters. ( 5.1 )"],"safetySignals":[{"llr":636.004,"date":"","count":139,"signal":"Adenovirus infection","source":"DrugCentral FAERS","actionTaken":"Reported 139 times (LLR=636)"},{"llr":584.188,"date":"","count":184,"signal":"Cytomegalovirus infection","source":"DrugCentral FAERS","actionTaken":"Reported 184 times (LLR=584)"},{"llr":456.738,"date":"","count":106,"signal":"Acute graft versus host disease in skin","source":"DrugCentral FAERS","actionTaken":"Reported 106 times (LLR=457)"},{"llr":456.142,"date":"","count":100,"signal":"Human herpesvirus 6 infection","source":"DrugCentral FAERS","actionTaken":"Reported 100 times (LLR=456)"},{"llr":399.735,"date":"","count":91,"signal":"Graft versus host disease in skin","source":"DrugCentral FAERS","actionTaken":"Reported 91 times (LLR=400)"},{"llr":333.071,"date":"","count":83,"signal":"Cytomegalovirus infection reactivation","source":"DrugCentral FAERS","actionTaken":"Reported 83 times (LLR=333)"},{"llr":316.697,"date":"","count":136,"signal":"Mucosal inflammation","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=317)"},{"llr":294.564,"date":"","count":72,"signal":"Graft versus host disease in gastrointestinal tract","source":"DrugCentral FAERS","actionTaken":"Reported 72 times (LLR=295)"},{"llr":290.021,"date":"","count":346,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 346 times (LLR=290)"},{"llr":226.308,"date":"","count":67,"signal":"Cytomegalovirus viraemia","source":"DrugCentral FAERS","actionTaken":"Reported 67 times (LLR=226)"},{"llr":214.218,"date":"","count":35,"signal":"Adenovirus reactivation","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=214)"},{"llr":214.074,"date":"","count":63,"signal":"Acute graft versus host disease","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=214)"},{"llr":196.487,"date":"","count":155,"signal":"Product use in unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 155 times (LLR=196)"},{"llr":154.625,"date":"","count":39,"signal":"Acute graft versus host disease in intestine","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=155)"},{"llr":148.969,"date":"","count":45,"signal":"Skin toxicity","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=149)"}],"drugInteractions":[{"drug":"CYP2C19 and CYP3A4 substrates","severity":"major","mechanism":"GRAFAPEX (treosulfan) is a CYP2C19 and CYP3A4 inhibitor, which can increase the exposure of these substrates.","management":"Monitor for adverse reactions and reduce the dosage of the substrates as needed, if recommended in their prescribing information.","clinicalEffect":"Increased risk of serious or life-threatening toxicities due to minimal concentration changes."}],"commonSideEffects":[{"effect":"musculoskeletal pain","drugRate":"39%","_validated":true,"placeboRate":"27%"},{"effect":"stomatitis","drugRate":"38%","_validated":true,"placeboRate":"48%"},{"effect":"pyrexia","drugRate":"34%","_validated":true,"placeboRate":"36%"},{"effect":"nausea","drugRate":"33%","_validated":true,"placeboRate":"41%"},{"effect":"edema","drugRate":"29%","_validated":true,"placeboRate":"18%"},{"effect":"infection","drugRate":"23%","_validated":true,"placeboRate":"18%"},{"effect":"vomiting","drugRate":"22%","_validated":true,"placeboRate":"19%"},{"effect":"rash","drugRate":"17%","_validated":true,"placeboRate":"13%"},{"effect":"diarrhea","drugRate":"17%","_validated":true,"placeboRate":"18%"},{"effect":"headache","drugRate":"16%","_validated":true,"placeboRate":"18%"},{"effect":"febrile neutropenia","drugRate":"15%","_validated":true,"placeboRate":"11%"},{"effect":"abdominal pain","drugRate":"15%","_validated":true,"placeboRate":"13%"},{"effect":"hypertension","drugRate":"14%","_validated":true,"placeboRate":"21%"},{"effect":"hemorrhage","drugRate":"14%","_validated":true,"placeboRate":"14%"},{"effect":"fatigue","drugRate":"13%","_validated":true,"placeboRate":"15%"},{"effect":"constipation","drugRate":"12%","_validated":true,"placeboRate":"12%"},{"effect":"tachycardia","drugRate":"10%","_validated":true,"placeboRate":"5%"}],"contraindications":["Hypersensitivity to any component of the drug product."],"seriousAdverseEvents":[{"event":"fatal regimen-related adverse reactions","detail":"All fatalities were due to pulmonary adverse reactions.","severity":"serious","incidence":"1.9%"}]},"trials":[],"aliases":[],"company":"Medexus","patents":[{"applNo":"N214759","source":"FDA Orange Book","status":"Active","expires":"Oct 12, 2026","useCode":"U-4142","territory":"US","drugProduct":false,"patentNumber":"7199162","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TREOSULFAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:00:52.292702+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T04:00:52.292611+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Treosulfan","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T04:00:59.882099+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:02:07.274044+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:00:58.433998+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T04:00:52.367199+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TREOSULFAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:00:58.821717+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:00:51.114668+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:01:56.018693+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: MYELOSUPPRESSION GRAFAPEX causes severe and prolonged myelosuppression at the recommended dosage. Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Monitor hematologic laboratory parameters [see Warnings and Precautions ( 5.1 )] . WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. GRAFAPEX causes severe and prolonged myelosuppression. Hematopoietic stem cell transplantatio","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:00:51.114697+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA cross-linking agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:00:59.882047+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:01:42.681452+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL455186/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:00:59.526077+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions ( 5.1 )] Seizures [see Warnings and Precautions ( 5.2 )] Skin Disorders [see Warnings and Precautions ( 5.3 )] Injection Site Reactions and Tissue Necrosis [see Warnings and Precautions ( 5.4 )] Secondary Malignancies [see Warnings and Precautions ( 5.5 )] The most common adverse reactions (≥20%) are musculoskeletal pain, stomatitis, p","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:01:31.103427+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:01:33.146275+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA214759","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:00:51.114702+00:00"}},"allNames":"trecondi","offLabel":[],"synonyms":["treosulfan","threosulphan","treosulphan","tresulfan","trecondi"],"timeline":[{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from medac Gesellschaft fur klinische Spezialpraparate mbH to Medexus"},{"date":"2019-06-20","type":"positive","source":"DrugCentral","milestone":"EMA approval (medac Gesellschaft fur klinische Spezialpraparate mbH)"},{"date":"2030-01-21","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"},{"date":"2032-01-21","type":"negative","source":"FDA Orange Book","milestone":"ODE-513 exclusivity expires"}],"aiSummary":"Trecondi (treosulfan) is a marketed drug by Medexus used primarily for allogeneic HSCT in AML patients, with a key composition patent expiring in 2028. Its mechanism of crosslinking DNA to inhibit replication and cell division provides a strong therapeutic profile, distinguishing it from off-patent competitors like busulfan, which has 15 generics available. The primary risk is the potential erosion of market share due to the availability of multiple generic alternatives.","approvals":[{"date":"2019-06-20","orphan":true,"company":"medac Gesellschaft fur klinische Spezialpraparate mbH","regulator":"EMA"}],"brandName":"Trecondi","ecosystem":[{"indication":"Allogeneic peripheral blood stem cell transplant","otherDrugs":[{"name":"pegfilgrastim","slug":"pegfilgrastim","company":"Amgen"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"treosulfan","explanation":"","oneSentence":"","technicalDetail":"Treosulfan exerts its effects by forming interstrand crosslinks between DNA strands, thereby inhibiting DNA replication and transcription, and ultimately leading to cell death."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Treosulfan","title":"Treosulfan","extract":"Treosulfan, sold under the brand name Trecondi among others, is an alkylating medication given to people before they have a bone marrow transplant from a donor known as allogeneic hematopoietic stem cell transplantation. It is used as a 'conditioning' treatment to clear the bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. It is used together with another medicine called fludarabine in adults and children from one month of age with blood cancers as well as in adults with other severe disorders requiring a bone marrow transplant. It belongs to the family of drugs called alkylating agents. In the body, treosulfan is converted into other compounds called epoxides which kill cells, especially cells that develop rapidly such as bone marrow cells, by attaching to their DNA while they are dividing. DNA cross-linking is considered a primary mechanism underlying the pharmacological action of treosulfan, and epoxides formed from treosulfan may cross-link DNA via at least two chemical pathways.","wiki_history":"==History==\nTwo main studies showed that treosulfan is at least as effective as busulfan, another medicine used to prepare people for haematopoietic stem cell transplantation.\n\nIn one of the studies, involving 570 adults with acute myeloid leukaemia (a blood cancer) or myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced), 64% of patients given treosulfan (with fludarabine) had a successful transplant and were alive and disease-free after 2 years, compared with 51% of patients given busulfan (with fludarabine).\n\nIn an additional study in 70 children with blood cancers, 99% of children given treosulfan (with fludarabine) were alive three months after their transplant.\n\nEfficacy was evaluated in MC-FludT.14/L Trial II (NCT00822393), a randomized active-controlled trial comparing treosulfan to busulfan with fludarabine as a preparative regimen for allogeneic transplantation. Eligible patients included adults 18 to 70 years old with AML or MDS, Karnofsky performance status ≥ 60%, and age ≥ 50 years or hematopoietic cell transplantation comorbidity index [HCTCI] score > 2. There were 570 patients randomized to treosulfan (n=280) or busulfan (n=290).","wiki_society_and_culture":"== Society and culture ==\n=== Legal status ===\nTreosulfan was authorized for medical use in the European Union in June 2019,\n\nThe US Food and Drug Administration granted orphan drug designation to treosulfan in 1994, for the treatment of ovarian cancer; and in 2015, for conditioning treatment prior to hematopoietic stem cell transplantation in malignant and non-malignant diseases in adults and pediatric patients.\n\nIn February 2004, orphan designation (EU/3/04/186) was granted by the European Commission to medac Gesellschaft fuer klinische Spezialpräparate mbH, Germany, for treosulfan for the conditioning treatment prior to haematopoietic progenitor cell transplantation.\n\n=== Names ===\nTreosulfan is the international nonproprietary name.\n\nTreosulfan is sold under the brand names Trecondi."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2718","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TREOSULFAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TREOSULFAN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Treosulfan","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T16:04:17.470163","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T04:02:07.274406+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"busulfan","drugSlug":"busulfan","fdaApproval":"1954-06-26","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"exclusivity":[{"code":"NCE","date":"Jan 21, 2030"},{"code":"ODE-513","date":"Jan 21, 2032"},{"code":"ODE-514","date":"Jan 21, 2032"},{"code":"NCE","date":"Jan 21, 2030"},{"code":"ODE-513","date":"Jan 21, 2032"},{"code":"ODE-514","date":"Jan 21, 2032"}],"genericName":"treosulfan","indications":{"approved":[{"id":"treosulfan-allogeneic-hsct-in-aml","name":"Allogeneic HSCT in AML","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML)","diagnosticRequired":null,"brandNameForIndication":"Trecondi"},{"id":"treosulfan-allogeneic-hsct-in-mds","name":"Allogeneic HSCT in MDS","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS)","diagnosticRequired":null,"brandNameForIndication":"Trecondi"}],"offLabel":[],"pipeline":[]},"currentOwner":"Medexus","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"busulfan","brandName":"busulfan","genericName":"busulfan","approvalYear":"1954","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":["AML","MDS","Acute Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":132,"completionDate":"2035-03"},{"nctId":"NCT03980769","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-05","conditions":["Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder"],"enrollment":40,"completionDate":"2028-07-01"},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":["Bone Marrow Failure Syndrome","Congenital Amegakaryocytic Thrombocytopenia","Diamond-Blackfan Anemia","Hereditary Sideroblastic Anemia","Paroxysmal Nocturnal Hemoglobinuria","Shwachman-Diamond Syndrome","Hematologic Neoplasm With Germline GATA2 Mutation","Hematologic Neoplasm With Germline SAMD9 Mutation","Hematologic Neoplasm With Germline SAMD9L Mutation"],"enrollment":40,"completionDate":"2026-02-18"},{"nctId":"NCT04195633","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-25","conditions":["Acute Leukemia","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Adult Diffuse Large Cell Lymphoma","Anaplastic Large Cell Lymphoma","Burkitt Lymphoma","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Hodgkin Lymphoma","Lymphoblastic Lymphoma","Lymphoplasmacytic Lymphoma","Mantle Cell Lymphoma","Mixed Phenotype Acute Leukemia","Myelodysplastic Syndrome","Prolymphocytic Leukemia","Refractory Chronic Lymphocytic Leukemia","Refractory Follicular Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Small Lymphocytic Lymphoma"],"enrollment":60,"completionDate":"2029-03-12"},{"nctId":"NCT04994808","phase":"PHASE2","title":"Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-08-11","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"enrollment":23,"completionDate":"2026-07-16"},{"nctId":"NCT07316595","phase":"PHASE2","title":"Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-12-30","conditions":["HSCT","Nijmegen Breakage Syndrome","Treosulfan Based Conditioning"],"enrollment":24,"completionDate":"2030-12-31"},{"nctId":"NCT02349906","phase":"PHASE2","title":"Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2015-04","conditions":["Primary Immunodeficiencies","Inborn Errors of Metabolism","Haemoglobinopathies","Bone Marrow Failure Syndromes"],"enrollment":106,"completionDate":"2023-02-13"},{"nctId":"NCT05534620","phase":"PHASE1","title":"Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics","status":"RECRUITING","sponsor":"medac GmbH","startDate":"2024-02-01","conditions":["Acute Myeloid Leukaemia (AML)","Myelodysplastic Syndrome (MDS)","Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)"],"enrollment":36,"completionDate":"2026-12"},{"nctId":"NCT07232953","phase":"PHASE2","title":"Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2022-11-10","conditions":["Acute Myeloid Leukaemia (AML)","Hematopoietic Stem Cell Transplant (HSCT)"],"enrollment":82,"completionDate":"2027-06"},{"nctId":"NCT07214064","phase":"PHASE2","title":"Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2026-01","conditions":["AML (Acute Myeloid Leukemia)","MDS/AML","MDS (Myelodysplastic Syndrome)"],"enrollment":27,"completionDate":"2027-12"},{"nctId":"NCT07025824","phase":"PHASE2","title":"Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2025-09","conditions":["AML - Acute Myeloid Leukemia","MDS (Myelodysplastic Syndrome)"],"enrollment":220,"completionDate":"2028-12"},{"nctId":"NCT06861257","phase":"","title":"Treosulfan Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Recipients","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2021-02-24","conditions":["Pediatric Hematopoietic Stem Cell Transplantation","Malignant Disorders","Non-malignant Disorders"],"enrollment":70,"completionDate":"2025-12-31"},{"nctId":"NCT06756152","phase":"PHASE2,PHASE3","title":"Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2024-07-10","conditions":["Biphenotypic Acute Leukemia","Acute Lymphoblastic Leukemia","Myeloblastic Leukemia","Bilinear Leukemia","Malignant Lymphoma, Non-Hodgkin","Myelodysplastic Syndrome"],"enrollment":50,"completionDate":"2026-10-10"},{"nctId":"NCT05636787","phase":"PHASE2","title":"Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-06-06","conditions":["Multiple Myeloma"],"enrollment":120,"completionDate":"2028-04"},{"nctId":"NCT05807932","phase":"PHASE1,PHASE2","title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2023-06-26","conditions":["Myelodysplastic Syndromes","Secondary Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia"],"enrollment":38,"completionDate":"2028-01-30"},{"nctId":"NCT01949129","phase":"PHASE2,PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":["Acute Lymphoblastic Leukaemia"],"enrollment":1800,"completionDate":"2030-04"},{"nctId":"NCT06198842","phase":"PHASE2","title":"Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2023-11-22","conditions":["Nijmegen Breakage Syndrome"],"enrollment":10,"completionDate":"2029-01-31"},{"nctId":"NCT06199427","phase":"PHASE2","title":"PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2023-11-21","conditions":["Inborn Errors of Immunity"],"enrollment":100,"completionDate":"2027-12-31"},{"nctId":"NCT03961919","phase":"PHASE2","title":"Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant","status":"COMPLETED","sponsor":"Ciceri Fabio","startDate":"2009-02-10","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes","Transplant-Related Hematologic Malignancy"],"enrollment":15,"completionDate":"2021-12-31"},{"nctId":"NCT01063647","phase":"PHASE1,PHASE2","title":"Dose-range Finding Treosulfan-based Conditioning","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2001-11","conditions":["Hematological Malignancies"],"enrollment":56,"completionDate":"2006-06"},{"nctId":"NCT06083129","phase":"PHASE3","title":"Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-01","conditions":["GVHD"],"enrollment":324,"completionDate":"2028-11-01"},{"nctId":"NCT00796068","phase":"PHASE2","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02-24","conditions":["Acute Biphenotypic Leukemia","Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia in Remission","Blasts Under 5 Percent of Bone Marrow Nucleated Cells","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Myelodysplastic Syndrome (MDS)"],"enrollment":130,"completionDate":"2021-12-14"},{"nctId":"NCT03434704","phase":"PHASE2","title":"Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole","status":"COMPLETED","sponsor":"Ciceri Fabio","startDate":"2018-06-18","conditions":["Transplant-Related Hematologic Malignancy","Leukemia, Acute","Myelodysplastic Syndromes","Graft Vs Host Disease","Fungal Infection"],"enrollment":10,"completionDate":"2019-10-13"},{"nctId":"NCT01582048","phase":"PHASE2","title":"Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning","status":"TERMINATED","sponsor":"Prof. Dr. med. Wolfgang Bethge","startDate":"2012-04","conditions":["Patients Receiving Mismatched Allogeneic HCT"],"enrollment":9,"completionDate":"2016-08-17"},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":["Non-Neoplastic Hematologic and Lymphocytic Disorder"],"enrollment":98,"completionDate":"2020-06-10"},{"nctId":"NCT00860574","phase":"PHASE2","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02","conditions":["Accelerated Phase Chronic Myelogenous Leukemia","Adult Acute Lymphoblastic Leukemia in Remission","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Blastic Phase Chronic Myelogenous Leukemia","Childhood Acute Lymphoblastic Leukemia in Remission","Childhood Acute Myeloid Leukemia in Remission","Childhood Chronic Myelogenous Leukemia","Childhood Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia","de Novo Myelodysplastic Syndromes","Previously Treated Myelodysplastic Syndromes","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Secondary Myelodysplastic Syndromes","Untreated Adult Acute Lymphoblastic Leukemia","Untreated Childhood Acute Lymphoblastic Leukemia"],"enrollment":96,"completionDate":""},{"nctId":"NCT01894477","phase":"PHASE2","title":"Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-11","conditions":["Acute Myeloid Leukemia in Remission","Chronic Myelomonocytic Leukemia","Minimal Residual Disease","Myelodysplastic Syndrome","Myelodysplastic/Myeloproliferative Neoplasm","Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable"],"enrollment":102,"completionDate":"2022-06"},{"nctId":"NCT04728490","phase":"PHASE2","title":"Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective Study","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-01-30","conditions":["Myelofibrosis"],"enrollment":28,"completionDate":"2024-01-30"},{"nctId":"NCT04000698","phase":"PHASE3","title":"Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2019-10-15","conditions":["Refractory Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia"],"enrollment":25,"completionDate":"2022-12"},{"nctId":"NCT03963024","phase":"PHASE1","title":"Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT","status":"TERMINATED","sponsor":"IRCCS San Raffaele","startDate":"2014-02-12","conditions":["Irradiated Bone Marrow","Transplant-Related Hematologic Malignancy","Leukemia, Acute","Multiple Myeloma","Graft Vs Host Disease"],"enrollment":9,"completionDate":"2019-01-31"},{"nctId":"NCT00822393","phase":"PHASE3","title":"Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2008-11-24","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"enrollment":570,"completionDate":"2018-01-25"},{"nctId":"NCT04400045","phase":"PHASE2","title":"Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2020-05-22","conditions":["Nijmegen Breakage Syndrome"],"enrollment":10,"completionDate":"2023-05"},{"nctId":"NCT02333058","phase":"PHASE2","title":"Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2014-11-21","conditions":["Acute Lymphoblastic Leukaemias (ALL)","Acute Myeloid Leukaemias (AML)","Myelodysplastic Syndromes (MDS)","Juvenile Myelomonocytic Leukaemias (JMML)"],"enrollment":70,"completionDate":"2019-09-30"},{"nctId":"NCT00987636","phase":"PHASE3","title":"Study in Localized and Disseminated Ewing Sarcoma","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2009-10-01","conditions":["Ewing's Sarcoma"],"enrollment":907,"completionDate":"2019-03-31"},{"nctId":"NCT02048800","phase":"","title":"Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT","status":"COMPLETED","sponsor":"Great Ormond Street Hospital for Children NHS Foundation Trust","startDate":"2014-03","conditions":["Allogeneic Haematopoietic Stem Cell Transplantation"],"enrollment":61,"completionDate":"2017-07-31"},{"nctId":"NCT02670564","phase":"PHASE4","title":"ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)","status":"RECRUITING","sponsor":"Swiss Pediatric Oncology Group","startDate":"2013-04","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":1000,"completionDate":"2026-04"},{"nctId":"NCT02852083","phase":"PHASE2","title":"A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC","status":"UNKNOWN","sponsor":"University Hospital Regensburg","startDate":"2016-01","conditions":["Squamous Cell Lung Cancer","Non-Squamous Cell Lung Cancer","Non-Small Cell Lung Cancer"],"enrollment":86,"completionDate":"2020-07"},{"nctId":"NCT00427999","phase":"PHASE2","title":"Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-02","conditions":["Prostate Cancer"],"enrollment":67,"completionDate":"2015-08"},{"nctId":"NCT01772953","phase":"PHASE2","title":"Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2013-09","conditions":["Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)"],"enrollment":40,"completionDate":"2015-08"},{"nctId":"NCT01079013","phase":"PHASE2","title":"Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2010-03","conditions":["Non Hodgkin Lymphoma","Hodgkin Lymphoma"],"enrollment":40,"completionDate":"2018-04"},{"nctId":"NCT00491634","phase":"PHASE2","title":"Treosulfan-based Conditioning for Transplantation in AML/MDS","status":"COMPLETED","sponsor":"Dr. Avichai Shimoni MD","startDate":"2007-06","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"enrollment":24,"completionDate":"2014-06"},{"nctId":"NCT01423747","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2003-07","conditions":["Lymphoblastic Leukemia, Acute, Childhood;"],"enrollment":400,"completionDate":"2016-09"},{"nctId":"NCT01423500","phase":"PHASE3","title":"ALL-SCT BFM International- HSCT in Children and Adolescents With ALL","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2007-01","conditions":["Lymphoblastic Leukemia, Acute, Childhood;"],"enrollment":405,"completionDate":"2016-09"},{"nctId":"NCT00682305","phase":"PHASE2","title":"Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2007-03","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2013-08"},{"nctId":"NCT00170690","phase":"PHASE3","title":"Preference Study With Elderly Patients Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2004-08","conditions":["Ovarian Cancer"],"enrollment":123,"completionDate":"2012-04"},{"nctId":"NCT01810926","phase":"PHASE2","title":"T&B Depletion Non Malignant","status":"UNKNOWN","sponsor":"Franco Locatelli","startDate":"2011-09","conditions":["Graft Versus Host Disease"],"enrollment":130,"completionDate":"2016-10"},{"nctId":"NCT00925821","phase":"PHASE2","title":"Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2009-06","conditions":["Multiple Myeloma"],"enrollment":146,"completionDate":""},{"nctId":"NCT00253513","phase":"PHASE1,PHASE2","title":"Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":["Leukemia","Myelodysplastic Syndromes"],"enrollment":60,"completionDate":"2009-10"},{"nctId":"NCT01010243","phase":"PHASE1,PHASE2","title":"Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial","status":"UNKNOWN","sponsor":"University of Regensburg","startDate":"2009-10","conditions":["Multiple Myeloma"],"enrollment":54,"completionDate":"2016-10"},{"nctId":"NCT01063660","phase":"PHASE2","title":"Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2004-03","conditions":["Acute Myeloid Leukaemia"],"enrollment":75,"completionDate":"2007-07"},{"nctId":"NCT01062490","phase":"PHASE2","title":"Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2004-11","conditions":["Myelodysplastic Syndrome"],"enrollment":45,"completionDate":"2009-10"},{"nctId":"NCT00598624","phase":"PHASE2","title":"Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2005-09","conditions":["Leukemia","Chronic Myeloid Leukemia","Myelodysplastic Syndrome","Diffuse Large Cell Lymphoma","Hodgkin Lymphoma","Chronic Lymphocytic Leukemia","Multiple Myeloma"],"enrollment":175,"completionDate":"2010-12"},{"nctId":"NCT00779714","phase":"PHASE3","title":"Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC","status":"UNKNOWN","sponsor":"University of Wuerzburg","startDate":"2008-10","conditions":["Melanoma"],"enrollment":360,"completionDate":"2013-04"},{"nctId":"NCT00129155","phase":"PHASE2","title":"MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2005-02","conditions":["Hematological Malignancies","Allogeneic Transplantation"],"enrollment":30,"completionDate":""},{"nctId":"NCT00168870","phase":"PHASE2","title":"Study of Metastatic Ocular Melanoma","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2003-02","conditions":["Ocular Melanoma"],"enrollment":48,"completionDate":""}],"_emaApprovals":[{"date":"2019-06-20","status":"Authorised","company":"medac Gesellschaft fur klinische Spezialpraparate mbH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous"},"_patentsChecked":true,"crossReferences":{"NDDF":"004465","UNII":"CO61ER3EPI","CHEBI":"CHEBI:82557","INN_ID":"3103","RXNORM":"38508","UMLSCUI":"C0076959","chemblId":"CHEMBL455186","ChEMBL_ID":"CHEMBL455186","KEGG_DRUG":"D07253","DRUGBANK_ID":"DB11678","PUBCHEM_CID":"9882105","SNOMEDCT_US":"326774002","IUPHAR_LIGAND_ID":"8281","MESH_SUPPLEMENTAL_RECORD_UI":"C018404"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"medac Gesellschaft fur klinische Spezialpraparate mbH","relationship":"Original Developer"},{"period":"present","companyName":"Medexus","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.83 hours","clearance":"4.9 mL/min/kg","bioavailability":"97%","volumeOfDistribution":"0.59 L/kg"},"publicationCount":513,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AB02","allCodes":["L01AB02"]},"biosimilarFilings":[],"originalDeveloper":"medac Gesellschaft fur klinische Spezialpraparate mbH","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Medexus","companyId":"medexus","modality":"Small molecule","firstApprovalDate":"2019","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T04:02:07.274406+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}